Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TEV-56286 Dose A · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group 1: Single Ascending Dose (SAD1) | EXPERIMENTAL | - |
| Group 2: Single Ascending Dose (SAD2) | EXPERIMENTAL | - |
| Group 3: Single Ascending Dose (SAD3) | EXPERIMENTAL | - |
| Group 4: Single Ascending Dose (SAD4) | EXPERIMENTAL | - |
| Group 5: Multiple Dose (MD1) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| TEV-56286 Dose A | DRUG | oral administration |
| TEV-56286 Dose B | DRUG | oral administration |
| TEV-56286 Dose C | DRUG | oral administration |
| TEV-56286 Dose D | DRUG | oral administration |
| TEV-56286 Dose E | DRUG | oral administration |
| Placebo | DRUG | matching placebo |
Inclusion Criteria: * Participant is a healthy male or female with a body weight of ≥50 kg for males and ≥45 kg for females, and body mass index (BMI) of 18.5 to 32.0 kg/m2 inclusive. * Participant is 18 to 60 years of age inclusive, at the time of signing the informed consent form (ICF). * Female ...
TEV-56286 Dose A is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development, with a trial assessing different doses in healthy participants. The drug is not approved and is still in early-stage clinical testing.
TEV-56286 Dose A is being developed by Teva Pharmaceutical Industries Limited, a company traded on the New York Stock Exchange under the ticker TEVA. The drug is currently in Phase 1 clinical development.
TEV-56286 Dose A is in Phase 1 clinical development. It is an investigational drug being studied in a trial of healthy volunteers, and it has not been approved by regulatory authorities.
TEV-56286 Dose A is being evaluated in a Phase 1 trial with the identifier NCT07674940, titled 'A Trial to Assess TEV-56286 at Different Doses in Healthy Participants.' The trial is not yet recruiting and plans to enroll 60 participants.
TEV-56286 Dose A is a specific dose level of the investigational drug TEV-56286. The Phase 1 trial NCT07674940 is designed to assess TEV-56286 at different doses, with Dose A being one of the dose levels being studied.